Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/2445/56371

Abacavir/Lamivudine Versus Tenofovir/Emtricitabine in Virologically Suppressed Patients Switching from Ritonavir-Boosted Protease Inhibitors to Raltegravir
Martínez Chamorro, Esteban José; d'Albuquerque, Polyana M.; Perez, I.; Pich,J.; Gatell, José M.
Universitat de Barcelona
There are few clinical data on the combination abacavir/lamivudine plus raltegravir. We compared the outcomes of patients from the SPIRAL trial receiving either abacavir/lamivudine or tenofovir/emtricitabine at baseline who had taken at least one dose of either raltegravir or ritonavir-boosted protease inhibitors. For the purpose of this analysis, treatment failure was defined as virological failure (confirmed HIV-1 RNA ≥50 copies/ml) or discontinuation of abacavir/lamivudine or tenofovir/emtricitabine because of adverse events, consent withdrawal, or lost to follow-up. There were 143 (72.59%) patients with tenofovir/emtricitabine and 54 (27.41%) with abacavir/lamivudine. In the raltegravir group, there were three (11.11%) treatment failures with abacavir/lamivudine and eight (10.96%) with tenofovir/emtricitabine (estimated difference 0.15%; 95% CI -17.90 to 11.6). In the ritonavir-boosted protease inhibitor group, there were four (14.81%) treatment failures with abacavir/lamivudine and 12 (17.14%) with tenofovir/emtricitabine (estimated difference -2.33%; 95% CI -16.10 to 16.70). Triglycerides decreased and HDL cholesterol increased through the study more pronouncedly with abacavir/lamivudine than with tenofovir/emtricitabine and differences in the total-to-HDL cholesterol ratio between both combinations of nucleoside reverse transcriptase inhibitors (NRTIs) tended to be higher in the raltegravir group, although differences at 48 weeks were not significant. While no patient discontinued abacavir/lamivudine due to adverse events, four (2.80%) patients (all in the ritonavir-boosted protease inhibitor group) discontinued tenofovir/emtricitabine because of adverse events (p=0.2744). The results of this analysis do not suggest that outcomes of abacavir/lamivudine are worse than those of tenofovir/emtricitabine when combined with raltegravir in virologically suppressed HIV-infected adults.
Infeccions per VIH
Sida
Antiretrovirals
HIV infections
AIDS (Disease)
Antiretroviral agents
(c) Mary Ann Liebert, Inc., 2012
Artículo
info:eu-repo/semantics/publishedVersion
Mary Ann Liebert, Inc.
         

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

López-Dupla, M.; Maymó-Masip, E.; Martínez Chamorro, Esteban José; Domingo, P.; Leal, M.; Peraire, J.; Viladés, C.; Veloso, S.; Arnedo, M.; Ferrando-Martínez, S.; Beltrán-Debón, R.; Alba, V.; Gatell, José M.; Vendrell, J.; Vidal, F.; Chacón, M.R.
León, Agathe; Cáceres, César; Fernández, Emma; Chausa, Paloma; Martin, Maite; Codina, Carles; Rousaud, Araceli; Blanch, Jordi; Mallolas Masferrer, Josep; Martínez Chamorro, Esteban José; Blanco, Jose L.; Laguno, Montserrat; Larrousse Morellón, Maria; Milinkovic, Ana; Zamora, Laura; Canal, Neus; Miró Meda, José M.; Gatell, José M.; Gómez, Enrique J.; García, Felipe
Torres, Berta; Rallón, Norma I.; Loncá, Montserrat; Díaz Lorca, Maria Alba; Alós i Hernández, Llúcia; Martínez Chamorro, Esteban José; Cruceta, Anna; Arnaiz Gargallo, Juan Alberto; Leal, Lorna; Lucero, Constanza; León, Agathe; Sánchez, Marcelo; Negredo, Eugenia; Clotet i Sala, Bonaventura; Gatell, José M.; Benito, José M.; García Alcaide, Felipe
Torres, Berta; Rallón, Norma I.; Loncá, Montserrat; Díaz Lorca, Maria Alba; Alós i Hernández, Llúcia; Martínez Chamorro, Esteban José; Cruceta, Anna; Arnaiz Gargallo, Juan Alberto; Leal, Lorna; Lucero, Constanza; León, Agathe; Sánchez, Marcelo; Negredo, Eugenia; Clotet i Sala, Bonaventura; Gatell, José M.; Benito, José M.; García Alcaide, Felipe